XOMA Royalty Announces Closing of Its Acquisition by Ligand
Ligand Pharmaceuticals Incorporated has completed its acquisition of XOMA Royalty Corporation, purchasing all outstanding shares for $39.00 per share plus Contingent Value Rights related to pending litigation. Following the transaction, XOMA Royalty is no longer listed on Nasdaq. The acquisition enhances Ligand's portfolio of biotechnology royalty …